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Abstract
Background: The cancer transcriptome is difficult to explore due to the heterogeneity of
quantitative and qualitative changes in gene expression linked to the disease status. An increasing
number of "unconventional" transcripts, such as novel isoforms, non-coding RNAs, somatic gene
fusions and deletions have been associated with the tumoral state. Massively parallel sequencing
techniques provide a framework for exploring the transcriptional complexity inherent to cancer
with a limited laboratory and financial effort. We developed a deep sequencing and bioinformatics
analysis protocol to investigate the molecular composition of a breast cancer poly(A)+
transcriptome. This method utilizes a cDNA library normalization step to diminish the
representation of highly expressed transcripts and biology-oriented bioinformatic analyses to
facilitate detection of rare and novel transcripts.
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BMC Genomics 2009, 10:163 http://www.biomedcentral.com/1471-2164/10/163Results: We analyzed over 132,000 Roche 454 high-confidence deep sequencing reads from a
primary human lobular breast cancer tissue specimen, and detected a range of unusual
transcriptional events that were subsequently validated by RT-PCR in additional eight primary
human breast cancer samples. We identified and validated one deletion, two novel ncRNAs (one
intergenic and one intragenic), ten previously unknown or rare transcript isoforms and a novel gene
fusion specific to a single primary tissue sample. We also explored the non-protein-coding portion
of the breast cancer transcriptome, identifying thousands of novel non-coding transcripts and more
than three hundred reads corresponding to the non-coding RNA MALAT1, which is highly
expressed in many human carcinomas.
Conclusion: Our results demonstrate that combining 454 deep sequencing with a normalization
step and careful bioinformatic analysis facilitates the discovery and quantification of rare transcripts
or ncRNAs, and can be used as a qualitative tool to characterize transcriptome complexity,
revealing many hitherto unknown transcripts, splice isoforms, gene fusion events and ncRNAs,
even at a relatively low sequence sampling.
Background
The classic image of the mammalian transcriptome is
composed of a large assembly of spliced mRNAs, each
structured with a capped 5' end, a 5' untranslated region,
a coding sequence, a 3' untranslated region and a polyA
tail, together with a relatively well-defined set of non-pro-
tein-coding RNAs with different functions (ribosomal,
transfer, spliceosomal and small nucleolar RNAs), with
most of the genome thought to be genetically inert. Tran-
scriptome sequencing and annotation initiatives have
challenged this view by discovering that most of the
genome is actively transcribed to yield complex patterns
of interlaced and overlapping transcripts, including tens
of thousands long (>200 nt) non-protein-coding RNAs
(ncRNA) [1-3].
Non-coding RNAs (ncRNAs) have emerged as a diverse
and important class of functional transcripts, accounting
for approximately the 1.5% of the transcriptional output
of mammalian genomes [4,5]. The regulatory role of these
molecules has been clearly established for some species
such as microRNAs (miRNAs) or small nucleolar RNAs
(snoRNAs) [6,7]. In addition, although most have not yet
been studied, many of the observed long 'mRNA-like'
ncRNAs are differentially expressed and developmentally
regulated, and increasing numbers are being shown to
function in a range of processes in cell and developmental
biology [8-13].
Compared to wild-type, the cancer cell transcriptome is
grossly altered. Microarray studies have revealed a host of
aberrations (i.e. drastic changes in expression levels of
specific transcripts), and recent RNA-seq studies have
identified a set of cancer-specific transcripts and transcrip-
tional variants in tissues and cell lines [14-17]. Common
alterations found in tumors are gene fusions and aberrant
splicing isoforms [18,19]. Although prevalent in blood
tumors, gene fusions occur in all malignancies, and they
account for 20% of human cancer morbidity [20]. Alter-
native splicing is often deregulated in cancer, probably as
a consequence of quantitative alterations in the levels of
expression of splicing regulators [21]; however, many
examples of cancer-specific gene isoforms (CD44, BRCA1,
survivin etc), whose expression seem to correlate with the
disease, have been described in literature [22].
A link between ncRNAs and cancer is becoming increas-
ingly evident. For example, two ncRNAs, PCGEM and
DD3, are significantly over expressed in prostate cancer,
HULC expression is significantly associated with hepato-
cellular carcinoma [23] and MALAT1 is known to be over
expressed in several human carcinomas [24-26]. Addi-
tionally, genes encoding hundreds of highly conserved
ncRNAs are altered in a significant percentage of leukae-
mia and carcinomas [27].
To explore this complexity, we employed the Roche 454
deep sequencing technology [28] and biology-oriented
sequence analysis techniques to obtain a transcriptional
snapshot of a normalized primary breast cancer cDNA
library. Our approach is largely qualitative, aiming at the
identification of transcriptional events associated with the
cancer phenotype. These included gene fusions, gene dele-
tions, rare or aberrant transcriptional isoforms, ncRNAs,
and transcripts of unknown function (TUF); a subset of
interesting transcripts was validated using RT-PCR on the
RNA obtained from the original breast cancer sample as
well as from other eight carcinomas with the same histo-
type. Globally, our results demonstrate that direct pyrose-
quencing of a normalized human cDNA library coupled
with bioinformatic analysis complements quantitative
investigations of gene expression by providing an accurate
qualitative picture of a complex transcriptome, poten-
tially unraveling tissue or disease-specific transcriptional
events.Page 2 of 17
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cDNA library preparation, emulsion PCR and 
pyrosequencing
Polyadenylated RNA was isolated from a breast invasive
tumor sample (in situ lobular carcinoma, bilateral, with
elevated mitotic and proliferative index, G3, Tamoxifen
treated, identified by the code 1360), having a purity of
85–90%. cDNA was synthesized using Super SMART™
PCR cDNA Synthesis Kit (Clontech, Mountain View, CA).
Prior informed consent for the research use of biological
material from surgery was obtained for this sample. The
ethics committee of the Institute for Biomedical Technol-
ogies – National Research Council approved the use of
this biological sample for the study presented here. After
reverse transcription, the cDNA library was normalized to
obtain an equilibrated mix of low and high abundance
mRNAs using Kamchatka crab double-strand nuclease
(DSN) [29], as described in Additional file 1.
2.1 μg of normalized double stranded cDNA was sheared
by nitrogen nebulization following the manufacturer's
instruction (Roche, Basel, Switzerland). Ligation of the
nebulized sample to specific adaptors and preparation of
the single strand libraries (sstDNA) was performed as pre-
viously described [28]. After purification, nebulized
sstDNA preparation was quantitated by RiboGreen RNA
Quantitation Kit (Invitrogen Inc., Carlsbad, California).
Quality was assessed using an Agilent Bioanalyzer. All
purification steps were performed using MinElute PCR
Purification Kit (Qiagen, Hilden, Germany).
The sstDNA library was then amplified by emulsion PCR
performed in water-in-oil microvescicles. Each PCR reac-
tion was recovered by propanol emulsion breaking and
buffer washing and enriched for positive reaction beads.
The beads were then washed; the primers were annealed
and then counted using the Multisizer™ 3 Coulter Counter
(Beckman Coulter, Inc. Fullerton, CA, USA). The kits for
DNA fragmentation, polishing, capture on beads, emul-
sion PCR and sequencing were purchased from Roche
Diagnostics. Samples were loaded onto 70x75 PicoTiter-
Plate (PTP) and inserted in the 454 – Roche GS 20
Genome Sequencer for the pyrosequencing reaction.
Sequence redundancy reduction
Sequence reads were extracted from the raw pyrosequenc-
ing data following the manufacturer's technical documen-
tation. The technical redundancy in the dataset (perfect
sequence duplication) was removed using the NCBI nrdb
program, included in the downloadable Blast suite http:/
/www.ncbi.nlm.nih.gov/BLAST/download.shtml. After
mapping the remaining reads to the genome, we
employed a second sequence redundancy reduction step
for the analyses investigating the overlap between our
reads and genomic features such as ENCODE regions,
ncRNAs or genes. For this purpose, we used the CleanUp
Algorithm [30] to generate a new non-redundant dataset,
using stringent cut-off parameters (similarity > 98%, cov-
erage threshold > 98%). We used the Cap3 assembler [31]
to perform all the transcript assemblies.
Mapping to the transcriptome and genome
A detailed description of the bioinformatics methods used
in this part of the work can be found in Additional file 1.
All the database searches against known transcripts (such
as ESTs) were performed using the NCBI BlastN program.
Non-redundant sequence reads were compared with the
human genome using Blat [32]. All human full-length
transcripts annotated in UCSC database (all_mrna Table,
all Human mRNAs from GenBank, human genome
release hg18, March 2006) [33] were used as reference set
for the classification. We defined a read as 'spliced' when
mapping to a chromosome with a coverage > = 95% in at
least two parts separated by a gap > = 50 nt. We classified
a read as 'intragenic' when mapping at least partially
within a known gene (either in an exonic or intronic
region), otherwise it was classified as 'intergenic'. Addi-
tional criteria were used to build an 'exon-oriented' read
classification.
A collection of Conserved Sequence Tags (CSTs) [34,35],
obtained by a full-genome comparison of human and
mouse genomes, was compared to the genome mappings
of the cDNA reads, excluding reads located within known
exons, to evaluate both conservation and coding propen-
sity.
Bioinformatic identification of cancer-specific splice sites 
and fusion/deletion transcripts
The details of the bioinformatics strategy used for detec-
tion of gene fusions and deletions is described in detail in
Additional file 1. Briefly, we first detected alignments
(using reads at least 50-bp long) corresponding to puta-
tive chromosomal rearrangements and then identified
putative translocation-mediated interchromosomal
fusion transcripts by comparing the gene direction at the
predicted breakpoints with known exon boundaries.
Using a similar procedure, we identified intragenic dele-
tion events. Predictions were compared with data from
the chimerDB database [18].
To analyze cancer-associated splicing events we used the
ASAP II database [19], which catalogues validated cancer-
associated isoforms curated from EST sequencing data.
We identified deep-sequencing reads with high-quality
alignments and at least one splice site, and compared
them with 273 high-confidence cancer-specific splice sites
(LOD > = 3) from 198 genes in ASAP II database.Page 3 of 17
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The breast cancer cDNA library reads were aligned to
UCSC Known Genes FastA sequences (human genome
release hg18, 260.731 entries) using BLAST, and were clas-
sified on the basis of their genomic location. The conser-
vation profile of non-exonic reads was assessed using the
UCSC PhastCons17way conservation score. A total of four
different datasets were generated: intronic, extragenic,
desert conserved and desert non-conserved. These datasets
were subsequently cross referenced against CRITICA
ncRNA predictions [12], a subset of RNAdb [36], and
NONCODE [37]. Details of these bioinformatic analyses
are available in Additional file 1. In addition, we assessed
the overlap between cDNA reads and the ENCODE
project annotation of novel transcribed region of
unknown function [38] by intersecting high-quality
genome-wide mappings with the genomic coordinates of
the encodeRna Table at UCSC.
Biological validation of selected transcripts
Validation was performed by direct sequencing of the
cDNA library and RT-PCR. We used RNA obtained from
the original lobular breast cancer sample and from other
eight tumors and performed RT-PCR using an oligo (dT)
primer and SuperScriptTM II Reverse Transcriptase (Invit-
rogen Inc., Carlsbad, California) according to manufac-
turer's instructions. For fusion transcripts we sequenced
individual PCR products after cloning them into the
pCR®II-TOPO TA vector (Invitrogen Inc., Carlsbad, Cali-
fornia). Additional file five lists all the PCR primers and
their annealing temperatures, together with the results of
all validations experiments. Since we were investigating
rare transcripts detected from a normalized cDNA library,
we reasoned that RNA extracted directly from primary
samples could be the best source of genetic material for
validation.
Results and discussion
Assessment of the cDNA library normalization before and 
after deep sequencing
Aiming to detect rarely expressed transcripts, we comple-
mented the standard deep-sequencing protocol with a
normalization step. Reference genes, which are often
referred to as 'housekeeping genes', are frequently used to
normalize mRNA levels between different samples [39].
In order to assess the success of the cDNA library normal-
ization procedure before sequencing, PCR amplifications
with selected probes corresponding to reference genes
were performed. Three reference genes with different
expression levels were chosen for the analysis (Additional
file 1). A visual inspection of the amplification bands in
Figure 1 confirms that the normalization procedure
decreased the level of highly expressed transcripts and
increased the strength of the bands corresponding to low-
level transcripts. For example, the expression of GAPDH
(Glyceraldeide-3-phosphate dehydrogenase) is reduced
Assessment of the cDNA library normalization before sequencingFigure 1
Assessment of the cDNA library normalization before sequencing. RT-PCR amplification of three reference genes, 
each expressed constitutively but with different abundance in the cell, to test the normalization of the cDNA library before 
sequencing. X = control before normalization. N = normalized library.Page 4 of 17
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thine phosphoribosyltransferase 1) is increased.
To assess whether the library normalization was also
reflected in the 454 sequence output, we counted the
reads that could be unequivocally associated with ACTB
(Beta-actin), GAPDH and HPRT and compared them with
the abundance of these transcripts (from the same tissue
and pathological state as our experimental sample) in a
public EST library (see related Methods in Additional file
1). We applied a well-established statistical test for assess-
ing significant differences in digital gene expression pro-
files [40] and found that that the sequence sampling
reflects the normalization of the cDNA library, even at the
relatively shallow depth of sequencing accomplished with
454 (Table 1).
Statistics of the sequencing results
We used the NCBI nrdb software to filter out technical
redundancy from the sequence dataset. We obtained
251,262 non-redundant sequence reads, fitting approxi-
mately a normal distribution with a median length of 88
nt and the third quartile at 102 nt (Figure 2). After map-
ping the non-redundant reads to the genome (requiring a
minimum coverage of 70%), we obtained a second data-
set of 194,806 distinct sequences which excluded all reads
with uncertain mapping. A threshold of 98% identity,
98% coverage and a single match on the genome was then
used for comparisons with annotated transcripts, gene
structures, highly conserved genomic regions, ENCODE
regions, and ncRNAs, resulting in 132,113 reads (Table
2). This dataset was used for all the other statistics in this
section and will be referred to as the 98.98.1 dataset. The
98.98.1 dataset has been deposited at the EMBL Nucle-
otide Sequence Database as EST sequences with the Acces-
sion Numbers FN045784 to FN177896.
The aim of cDNA nebulization was to maximize the sam-
pling of sequence length. In order to evaluate the effective
coverage of full-length transcripts obtained with our pro-
tocol, we counted all the high-quality Blat matches of the
98.98.1 sequence reads dataset mapping to the human
RefSeq transcript database [http://www. ncbi. nlm.n
ih.gov/RefSeq/, April 2008]. A total of 11,551 different
RefSeq genes were identified with stringent parameters by
51,369 distinct sequence reads, corresponding to the 39%
of the 98.98.1 dataset. Analysis of tag density across Ref-
seq transcripts showed that cDNA nebulization generated
reads randomly covering the whole length of a transcript,
although with a clear oversampling of 3'untranslated
regions (3'UTR) (Figure 3). This is not an unexpected find-
ing, since RT-PCR followed by cDNA synthesis is necessar-
ily biased toward the 3' end of the transcript, unless
controlled partial hydrolysis of RNA is performed before
retrotranscription [41].
One effective way of exploring molecular diversity by
sequencing is through analysis of mRNA 3'UTRs, which
are rich in single-feature polymorphisms that distinguish
closely related transcripts. The specificity of 3'UTR
sequences allows effective annotation of individual
mRNAs without assembly of complete cDNAs and can be
useful in transcriptome profiling by sequencing [42].
However, caution should be used in data interpretation,
as there is some evidence that 3'UTRs may be separately
expressed (Wilhelm, Soldà, Mercer, Dinger, Simons, Gla-
zov, Koopman and Mattick, unpublished data). We used
the non-redundant dataset of human 3'UTRs (39,758
sequences) from UTRdb, a curated database of 5' and 3'
untranslated sequences of eukaryotic mRNAs [43], as a
target for the 98.98.1 sequence reads dataset, requiring
perfect identity and coverage of at least 90% to accept a
match. From a total of 18,262 matches to the UTRdb we
obtained 9,178 reads which could be univocally associ-
ated with a single RefSeq transcript (~50% of the
matches). We conclude that the 454 reads mapping with
high quality on a transcriptome have a high 'resolution
power', or ability to distinguish between transcript vari-
ants
Genomic classification of sequence reads
In order to characterize and annotate the breast cancer
transcriptome, we mapped each read on the human
genome and extracted all features associated with that tar-
get region. We then employed a hierarchical classification
based on multiple criteria; the results are summarized in
Table 3 and detailed in Additional file 2.
Table 1: Assessment of the cDNA library normalization by sequence count
Reference Gene1 454 Reads mapped to the genome (194,806) UniGene ESTs
(39,700)
Probability of differential expression between 
the libraries
ACTB 11 187 Prob > 0.999
GAPDH 31 225 Prob > 0.999
HPRT1 7 0 0.5 < Prob < 0.6
1 ACTB and GAPDH are abundantly expressed housekeeping genes, while HPRT1 is expressed at low levels.Page 5 of 17
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in two large datasets: 'spliced' and 'unspliced' reads (see
Methods). The 'unspliced' dataset was split into intragenic
or intergenic. Intragenic reads were then assigned to 4 dif-
ferent classes: exon, intron, extended 5' and extended 3'.
The 'spliced' dataset was also classified by location within
a gene. In order to detect potentially novel transcriptional
features we excluded the entire unspliced-exon dataset
from further analyses, as this will mostly contain well-
known entities. We noticed that there are a significant
number of matches in the intragenic non-exonic portion
of genes, which we attribute to new exons, retained
introns or intronic transcripts.
Genome-wide identification of coding and non-coding
Conserved Sequence Tags (CST) in human and mouse
genomes [34,35] provides a dataset of genome coordi-
nates which can be correlated with our deep sequencing
reads, especially those associated with putative novel tran-
scripts. The distribution of the CSTs, divided in four cate-
gories (undefined; non-coding; coding; ultraconserved),
is reported in Figure 4 and shows the normalized ratio
between the numbers of the Conserved Sequence Tags in
each category with the corresponding number of cDNA
Table 2: Primary classification of the 454 sequencing reads
Set Description Number of reads
Total (unfiltered) 251,262
Mapping to the genome, 70% coverage, high stringency 194,806
Subset with a single match on the genome at 98% identity and 98% coverage (98.98.1 dataset)1 132,113
Subset with a single match on the genome and 100% coverage of the alignment2 114,427
Subset of 98.98.1 dataset matching with max 6 errors (mismacthes + indels) and 90% coverage on UCSC all_mrna and RefSeq – canonical 
transcripts dataset
59,632
Subset of 98.98.1 dataset matching inside an UCSC Known Gene (Intragenic dataset, intronic + exonic transcripts) 118,840
Matching with max 6 errors 
(mismatches + indels) and 90% coverage to the Human ORESTES EST dataset (764,587 sequences)
68,396
1 Reference dataset
287% of the reference dataset. This set was used for genomic classification (Table 3)
Distribution and statistics of the cDNA readsFigure 2
Distribution and statistics of the cDNA reads. Distri-
bution and statistics of the non-redundant cDNA sequences 
for the initial nebulized 454 reads dataset (251,262 
sequences). The independent variable (X axis) is the read 
length, the dependent variable is the sequence count corre-
sponding to each length bin. The red line is an approximation 
to a normal distribution, with mean of 85.6 and an estimate 
dispersion of 22.1
Uniformity of sequence coverage across transcriptsFigure 3
Uniformity of sequence coverage across transcripts. 
Sampling of an 'ideal' complete target transcripts by the 
98.98.1 read dataset. 0 means that the 454 sequence identi-
fies a point at the 5' of the target RefSeq transcript, while a 
value of 100 correspond to a sampling of the 3' end. The 
upper box is an Outlier Box plot, representing the interquar-
tile range, the mean and the limits of the outliers. The red 
line represent the shortest area in which 50% of the data are 
represented. The total number of matches represented in 
this plot is 74,208.Page 6 of 17
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the number of high-quality matches for each of the reads:
one single match on the genome; from 2 to 10 and more
than 10. The sequences which match only once on the
genome show an equal distribution between overlapping
coding and non-coding CSTs, while sequences with mul-
tiple matches tend to overlap conserved regions with high
coding potential.
Identification and primary validation of potential cancer-
associated transcriptional events
Detailed bioinformatic analyses were performed on our
breast cancer library to identify fusion transcripts, aber-
rant or novel splicing isoforms, as well as known cancer-
related splice variants (see Methods and Additional file 1).
In total, we found 477 putative rearrangement events. It
must be noted, however, that we expected the rate of false
positives to be high, due to sequencing or PCR artifacts. A
manually curated selected dataset, including only reads
containing at least one end in proximity of a splice site,
identified six putative translocation-mediated fusion
events and two intragenic deletions; the relative sequences
in FastA format are available from Additional File 3 and
the genome mapping and annotation are in Additional
file 4.
Fusion transcripts can be derived from either trans-splic-
ing of separate pre-mRNA molecules [44] or from tran-
scription of rearranged chromosomal regions in which
sections of two separate chromosomes have been joined
by translocation, deletion, or inversion [16,17]. A poten-
tially interesting fusion event was detected from the
sequence 107781_1044_1738 (115 nt long), which we
renamed 4A, involving two genes located on different
chromosomes: UBR4 (ubiquitin protein ligase E3 compo-
nent n-recognin 4) on chromosome 1 and GLB1 (beta-
galactosidase-like protein) on chromosome 3. UBR4,
commonly known as p600 or retinoblastoma protein-
associated factor 600, is a cellular target of the human
papillomavirus type 16 E7 oncoprotein, contributing to
anchorage-independent growth and cellular transforma-
tion. UBR4-E7 interaction strongly contributes to cellular
transformation [45]. The GLB1 gene encodes beta-galac-
tosidase-1 (EC 3.2.1.23), a lysosomal hydrolase that
cleaves the terminal beta-galactose from ganglioside sub-
strates and other glycoconjugates. The predicted fusion,
verified by direct sequencing of the original cDNA library,
links exon 16 of the gene UBR4 with the terminal exon
(composed of coding and 3'UTR sequence) of the GLB1
gene. Our sequence is colinear with both transcripts and
exon-exon junctions are clear in the hybrid sequence. The
Table 3: Genomic classification of the 454 sequencing reads
Sequence class Number of reads
Intergenic Unspliced 6,298
Intergenic Spliced 402
Intragenic Unspliced – total 97,690
3 TERM 2,475
(Poli-A) (989)
(INTERNAL) (1,486)
5 TERM 2,807
(TSS) (1,113)
(INTERNAL) (1,694)
EXON 1,331
INTRAEXON 64,326
INTRON 26,751
Intragenic Spliced 10,037
Total 114,427
Abbreviations: 3 TERM, read which extend the annotated 3'term of 
the target gene. Poli-A: read which extends at 3' the last exon. 
INTERNAL: read which extends at 3' any exon except the last. 5 
TERM: read which extend the annotated 5' term of the target gene. 
TSS: read which extends at 5' the first exon. INTERNAL: read which 
extends at 5' any exon except the first. EXON: read mapping inside 
an exon with one or both ends coincident with exon boundaries. 
INTRAEXON: read mapping completely inside an exon of the target 
gene. INTRON: read mapping completely inside an intron.
Distribution of Conserved Sequence Tags (CST) in relation w th cDNA genome mappingFigure 4
Distribution of Conserved Sequence Tags (CST) in 
relation with cDNA genome mapping. Plot of the per-
centage of the CST conserved segments overlapping cDNA 
reads for each of the following categories: matching only 
once in the genome; matching from 2 to 10 times; matching 
more than 10 times. CST_UC = CST with unknown coding 
potential; CST_COD = CST with coding potential; 
CST_NCOD = CST without coding potential; CST_UND = 
undetermined coding potential.Page 7 of 17
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be 14,022-bp long and would produce a large protein of
4,526 residues, which is shorter than the original UBR4
protein (5,183 residues). The UBR4/GLB1 fusion protein
is identical to UBR4 up to residue 4,433, and then
diverges significantly (Figure 5). Fusion transcripts are
common in haematological malignancies and they are
also recognized as contributing to the pathogenesis of
solid tumors [20]. Our sequencing approach thus allowed
the reliable detection of one novel cancer-related gene
fusion which we subsequently validated at the transcript
level in the original sample, although we could not repli-
cate clearly this finding in the other eight breast cancer
RNAs examined (Additional file 5). Recent papers, which
appeared while this work was under review, highlighted
that a particular cancer cell line or tissue can harbour mul-
tiple gene fusions, many of which are likely not recurrent,
in accordance with our results [16,17]. Further refine-
ments to the current protocol, such as paired-end
sequencing or coupling of long with short reads, will be
more effective in the specific identification of fusion
events. Indeed, a recent study using Paired-End diTags
Identification of a UBR4/GBL1 fusion transcriptFigure 5
Identification of a UBR4/GBL1 fusion transcript. (A, B) Details at the nucleotide level of the fusion event. Splice junctions 
are indicated in red. (C) alignment of the divergent parts of the original GLB1 peptide and of the fusion UBR4-GLB1. Residues 
before 4,433 are identical. The yellow and green background identifies identical or conserved residues.Page 8 of 17
(page number not for citation purposes)
BMC Genomics 2009, 10:163 http://www.biomedcentral.com/1471-2164/10/163(PETs) in cancer cell genomes detected 70 new fusion
transcripts [46].
An example of a transcriptional or genomic deletion event
is provided by sequence read 1B (167378_1645_3303),
located on chromosome 8. We interpret this sequence as
a deletion, probably due to a loop that causes the inclu-
sion of exons 2 and 7 of the WHSC1L1 gene in an inverted
order in the mature transcript (Figure 6). This transcript
was also confirmed by direct sequencing of the cDNA
library and by RT-PCR in an additional breast cancer sam-
ple (Additional file 5). The WHSC1L1 gene is related to
the Wolf-Hirschhorn syndrome candidate-1 gene and
encodes a protein with PWWP (proline-tryptophan-tryp-
tophan-proline) domains. Two alternatively spliced
WHSC1L1 variants have been described. The long isoform
contains a PHD-finger domain (an interleaved type of Zn
finger chelating 2 Zn ions) and a SET domain (protein-
protein interaction domain); however, the function of the
protein has not been determined yet and hence the rele-
vance to cancer aetiology of this deletion is uncertain.
The median length of the sequence reads in this sequenc-
ing run was around 85 nt, which is considerably longer
than what can be achieved with other deep sequencing
technologies, although much shorter than the length
achievable with the latest generation of 454 sequencers
(FLX and Titanium). This read length made it possible to
identify interesting transcripts (ncRNAs; novel isoforms;
fusions; deletions) without any sophisticated molecular 'a
priori' processing of the RNA, apart from library normali-
zation. This approach may be particularly useful to
researchers investigating the transcriptome of species with
poor genome annotation.
Taking advantage the length of 454 sequencing reads we
investigated alternative splicing events, which are known
to be significantly altered in breast tumors and can be
used to identify normal and cancerous breast tumor tissue
[47]. We identified a 102 nt read, 045624_1590_1179
(which we renamed 6B), which corresponds to a known
isoform spanning the Variable, Light and Join segments of
Unigene cluster 449585, Immunoglobulin lambda join-
ing 3, on chromosome 22q11.1-q11.2. When mapped to
the genome, this read aligns to three different exons, the
second and the third being separated by ~511,000 bases
(Additional file 4). This rare isoform was validated both
by direct sequencing of the cDNA library and by RT-PCR
of the original RNA, but was not detected in any other
breast cancer sample tested (Additional file 5). We also
identified splice isoforms that had not previously been
reported. The 119 nt read 023612_1809_1670, renamed
AI4, spans a splice junction of the gene BC031316 and is
supported by three spliced ESTs but by no full-length
mRNA. This isoform was confirmed by direct sequencing
on the original cDNA library (Figure 7) and was detected
by RT-PCR in multiple additional breast cancer samples
(Additional file 5).
Specific cancer-associated transcript isoforms have been
predicted based on differential representation of ESTs
between tumor and healthy tissues. When we queried the
ASAPII database of alternative splicing with our deep
sequencing reads we identified five putative cancer-associ-
ated isoforms, one of which has a plausible role in breast
cancer biology. Isoform b of HIGD1A (HIG1 domain fam-
ily, member 1A) gene (Figure 8) encodes a protein con-
taining a domain likely to be involved in the hypoxia
response. Growth and progression of breast cancers are
accompanied by increased neovascularization (angiogen-
esis) and a variety of factors, including hypoxia, contrib-
ute to increased production of angiogenic factors [48].
The HIGD1A variant (isoform b) identified by deep
sequencing contains a distinct 5'UTR and lacks a portion
of the 5' coding region, compared to variant a. These dif-
Identification of a deletion within the WHSC1L1 geneFigure 6
Identification of a deletion within the WHSC1L1 gene. 
(A, B) Alignment of the read 1B with the corresponding 
genome regions of WHSC1L1. Splice junction nucleotides are 
indicated in red. (C) Schematic representation of the putative 
intragenic deletion, (probably due to a looped transcript) in 
WHSC1L1, identified by the read 1B. The green and blue 
arrows represent the two halves of the fusion transcript 
which map on the opposite order to the genome.Page 9 of 17
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and a protein with a shorter N-terminus. The predicted
association with cancer is strongly supported by the
ASAPII LOD score for this transcript [49]. Our data sug-
gest that specific isoforms of HIGD1A are expressed in
breast cancer and may be associated with the disease state.
Experimental validation of selected transcript variants 
identified with bioinformatic analysis
A subset of the above-described transcripts, including
some potential cancer-associated variants, were selected
for biological validation by RT-PCR on RNA derived from
the same tissue sample that was used for deep sequencing,
as well as from other eight lobular breast cancers. Ampli-
fication products from the original sample were assessed
by Sanger sequencing. We obtained experimental confir-
mation of one deletion, one novel intergenic transcript,
one novel intragenic transcript, nine previously unanno-
tated isoforms – two associated with exon skipping and
seven with novel splice site usage – and one known, but
rare isoform. A gene fusion event which we detected by
deep sequencing could be validated only in the original
sample. These results, the primer sequences, the transcript
labels and the PCR product sizes are described in Addi-
tional file 5.
Detection of known and novel non-coding RNAs and of 
putative new transcriptional units
A number of approaches are currently available to dis-
criminate protein-coding transcripts from ncRNAs [50].
Identification of a novel isoform of the BC031316 geneFigure 7
Identification of a novel isoform of the BC031316gene. (A) Alignment of the sequence read AI4 with the human genome. 
(B) UCSC human genome screenshot showing the novel isoform, with a longer first exon, of the annotated BC031316 gene, 
identified by the sequence read AI4 and further supported by many annotated spliced ESTs.Page 10 of 17
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sequences that could represent real matches with ncRNAs
is a direct sequence comparison with stringent criteria and
an appropriate error model for 454 sequencing reads [51]
(see Methods). In order to examine the expression of
ncRNAs in our breast cancer sample, we first screened
known ncRNAs selected from two independent non-cod-
ing RNA databases: RNAdb and NONCODE [36,37]. In
total, 98 sequences corresponding to known ncRNAs were
detected in our library (Table 4 and Additional file 6).
Interestingly, some of them such as SRA1 and MALAT1,
have previously been associated with other tumor types
and might also play a role in breast cancer pathogenesis.
The steroid receptor RNA activator (SRA) is a unique mod-
ulator of steroid receptor transcriptional activity that func-
tions as a regulatory RNA assembled in a
ribonucleoprotein complex. Recent findings, however,
have shown that the SRA1 locus can produce both pro-
Identification of a putative cancer-associated isoformFigure 8
Identification of a putative cancer-associated isoform. UCSC genome screenshot showing the region where the 
176265_1466_0318 read maps, clearly identifying the shorter protein isoform (1b) of HIGD1A, which is predicted to be signifi-
cantly associated with the 'cancer' phenotype according to ASAPII EST and transcript analysis. The black block identified as 
27858 is the ASAPII intron associated with the cancer-specific HIGD1A isoform 1b splice site.
Table 4: Annotation of the non-coding part of the transcriptome
ncRNA class Number of unique ncRNAs matching the breast cancer library4
Small RNAs: 24
piRNAs 23
scAluRNAs 1
Long regulatory RNAs1: 35
Host genes2 11
Imprinted transcripts 4
Antisense transcripts 9
Cancer associated transcripts 11
TUF 26
Expressed pseudogenes 11
Predicted conserved secondary structure3 2
Total 98
1 The same regulatory RNA may belong to more than one subclass.
2 Both miRNA and snoRNA host transcripts are considered.
3 According to RNASearch predictions [61].
4 Known ncRNAs were retrieved from both RNAdb and NONCODE databases (see Methods)
Abbreviations: piRNA, Piwi-associated small RNAs; scAluRNA, small cytoplasmic Alu-repeat RNAs; TUF, transcripts of unknown function.Page 11 of 17
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involved in the regulation of estrogen and androgen
receptor signaling pathways. Moreover, several reports
have shown increased SRA expression in breast, uterus
and ovarian cancers, and a possible direct involvement of
SRA transcript in the mechanisms underlying breast tum-
origenesis and tumor progression has been proposed [52].
The most abundant ncRNA we detected was MALAT1
(metastasis associated lung adenocarcinoma transcript 1).
MALAT1 is a conserved 8-kb ncRNA whose expression
correlates with the risk of developing metastasis in non-
small-cell lung cancer (NSCLC) patients. Recent studies
have also reported the overexpression of MALAT1 in uter-
ine endometrial stromal sarcoma and hepatocellular car-
cinoma [25,26]. We found 309 reads mapping along this
regulatory ncRNAs, which, when assembled with the cap3
program [31], gave rise to 14 contigs (sequences available
in Additional file 3) distributed along all the length of the
ncRNA (Figure 9). Interestingly, only 6 of the 309 reads
map to portion of MALAT1 which is cleaved in the
nucleus and generates a cytoplasmic tRNA molecule [53].
This observation suggests that MALAT1 is abundantly
expressed in our primary sample, in accordance with pre-
vious results [26], and prompted us to further investigate
this finding.
We found that MALAT1 is abundantly expressed in all the
publicly available annotated breast cancer samples
retrieved from the CleanEx database http://
www.cleanex.isb-sib.ch/[54]. Detailed analysis of an
Affymetrix ER+ Tamoxifen-treated and untreated breast
cancer data set [55] showed a relevant variation in
MALAT1 transcript abundance, including a few outliers
with very high expression of this ncRNA. Further analysis
of cDNA microarrays, probed with total polyA+ RNA from
ER+ lobular and ductal breast cancers treated with
Tamoxifen, showed the same expression patterns [56].
This reinforces our finding that high MALAT1 expression
may be episodically associated with single breast tumors
and that the sensitivity of our deep sequencing approach
facilitated the detection of this ncRNA in our sample. We
also noticed that the Coefficient of Variation of gene
expression values was higher in Tamoxifen-treated versus
Tamoxifen-untreated breast cancer samples (84% versus
43% for the Affymetrix array experiments dataset) (Addi-
tional file 5).
Surprisingly, we found 23 reads corresponding to PIWI-
interacting RNAs (piRNAs), which are thought to be selec-
tively expressed in male and female gonads and are
important for the control of transposable elements during
germline development [7]. However, piRNA expression in
Abundant representation of MALAT1 ncRNA in 454 sequences from the breast tumor sampleFigure 9
Abundant representation of MALAT1 ncRNA in 454 sequences from the breast tumor sample. UCSC human 
genome screenshot of the region containing the MALAT1 locus. 309 cDNA reads map with high confidence along MALAT-1, a 
ncRNA highly correlated with poor prognosis in several tumor types. These were assembled in 14 contigs, which are reported 
in the figure.
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piRNA biogenesis that is not confined to the germline has
recently been described [57].
Sequences that mapped to 'gene deserts', which lie at least
2 kb from the boundaries of any known transcript, and
which resulted highly conserved according to UCSC
PhastCons17, were manually examined for overlap with
ESTs, transcript predictions and non-coding RNAs anno-
tations derived from CRITICA [2,8,58]. Eleven per cent
(684 of 5,950) of the reads that mapped to 'gene deserts'
actually overlap CRITICA-predicted non-coding tran-
scripts or are supported by EST data. These reads likely
represent non-protein-coding genes (Additional file 6 and
Figure 10), or exons at a significant distance (greater than
5 kb) from a gene, belonging to exceptionally extended
3'UTRs. In agreement with our data, evidence of extended
3'UTR has been recently reported in a deep-sequencing
screen of the mouse transcriptome [41]. We also com-
pared the reads mapping at least 5 kb from any known
transcript (1,069 sequences) with a collection of
sequences that are highly conserved between human and
mouse and which are classified in order of coding poten-
tial (CSTs) [35]. We were able to identify 314 reads over-
lapping one or more CSTs with coding potential, and a
further 351 reads overlapping non-coding CSTs. These
results suggest that our deep sequencing and bioinformat-
ics protocols are capable of detecting rare and novel tran-
scripts outside known gene structures (Additional file 7).
The ENCODE annotation of transcriptionally active
regions [38] (Transcripts of Unknown Function: TUFs)
covers only 1% of the genome. However, we found 135
reads that overlap with 60 distinct ENCODE TUFs. We
identified individual TUFs with both single and multiple
reads, confirming our protocol's efficacy in enriching for
non-canonical transcripts (Additional file 8).
Functional annotation of the coding part of the sequenced 
transcriptome
Functional annotation of transcripts has become an
important aspect of microarray studies, and many tools
are now available to assess gene expression biases [59].
Using the functional annotation strategies that are usually
applied to microarray experiments functional annotation,
we examined the genes identified by deep sequencing.
454 reads mapped to 6.067 RefSeq transcripts (Additional
file 9) with counts per transcript ranging from 82 to 1,
with median of 2. AKAP9, which interacts with multiple
signal transduction pathways, had the highest number of
counts, followed closely by the ncRNAs MALAT1 and
XIST. Among transcripts with very few counts we identi-
fied a number of annotated pseudogenes.
We applied the DAVID on-line analytical tool [60] to
identify enrichment of specific Gene Ontology (GO)
terms among the genes which had at least two cDNA read
counts (3,589 genes). The most enriched categories are
related with protein and nucleic acid binding and with
catalysis, as expected in an actively proliferating tissue
(Figure 11).
Conclusion
Quantitative transcriptional analysis of all the genes
expressed by breast tumors has provided the first steps
towards defining a molecular signature for the disease,
and might ultimately make conventional diagnostic tech-
niques obsolete. The qualitative analysis of the breast can-
Identification of a novel conserved noncoding transcriptFigure 10
Identification of a novel conserved noncoding transcript. UCSC human genome 8 kb screenshot of a "gene desert 
region" (no known gene in a 50 kb boundary) on the X chromosome tagged as transcribed by the sequencing read 
002770_3171_2414. The read overlaps a CRITICA-predicted putative noncoding transcript (CR621898) and points to a new, 
highly conserved transcriptional island, according to a vertebrate 28 multi-species alignment and PhastCons conservation 
score.Page 13 of 17
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BMC Genomics 2009, 10:163 http://www.biomedcentral.com/1471-2164/10/163cer transcriptome – such as the one obtained by massive
cDNA sequencing and presented here – should instead
contribute different and complementary information: the
identification of novel possible pathogenic determinants
(gene fusions and genome deletions) or biomarkers
(aberrant or novel transcripts and isoforms, intronic and
extragenic ncRNAs, expressed pseudogenes).
We demonstrated in this work that 454 deep sequencing
of a normalized cDNA library, coupled with detailed biol-
ogy-oriented bioinformatic analyses, has the potential to
identify transcripts that may further our understanding of
the breast cancer transcriptome, even starting from a rela-
tively small number of sequences. In our primary breast
cancer cDNA library and in a number of additional sam-
ples with a matching histotype, we have identified and
validated several unusual transcriptional events that could
be suitable for subsequent functional studies: gene
fusions, gene deletions, novel or cancer-associated iso-
forms and putative novel ncRNAs.
We have also identified from our sequences a very high
expression of the cancer-associated MALAT1 ncRNA and
we replicated this observation in two different gene
expression profiling experiments of well-annotated ER+
breast cancer patient cohorts, finding also an high vari-
ance between Tamoxifen treated and untreated patient
samples. Although further technical refinements, such as
controlled hydrolysis of RNA samples before cDNA syn-
thesis and paired-end or di-tags sequencing, can increase
significantly the number and diversity of sequences which
can be annotated, our protocol has proved to be very
effective in detecting rare or novel transcriptional events.
Based on the results presented here, we are confident that
further deep sequencing experiments and a similar bioin-
formatic analysis strategy will yield an even more compre-
hensive and detailed picture of the breast cancer
transcriptome.
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